Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × Atrasentan × Clear all

Phase

Phase 3 2 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 24 Cisplatin 24 Gemcitabine 23 Carboplatin 23 Paclitaxel 22 Pemetrexed 13 Docetaxel 13 Drug Therapy 12 Capecitabine 12 Oxaliplatin 11 Bevacizumab 10 Nivolumab 9 Fluorouracil 9 130-nm albumin-bound paclitaxel 8 anlotinib 7 Trastuzumab 7 Temozolomide 5 atezolizumab 4 Rituximab 4 Leucovorin 4 Lenalidomide 4 Irinotecan 4 Ipilimumab 4 Injections 4 Folfox protocol 4 venetoclax 3 pertuzumab 3 osimertinib 3 daratumumab 3 camrelizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00127478 2007-11-29

A Long Term Safety Study With Atrasentan

Abbott

Phase 2/3 Completed

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡